CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

But while an improved reputation can be a by-product of patient engagement, it should not be the driving force behind it.

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

AGC Biologics’ Milan site achieved its 10th product approval from a major regulatory body after the EU granted marketing authorization for AUCATZYL®.

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.

Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...